Last €77.05 EUR
Change Today -9.44 / -10.91%
Volume 955.3K
MOR On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 3:52 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Arndt Schottelius

Chief Development Officer and Member of Management Board, Morphosys AG
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

48€1,283,331
As of Fiscal Year 2013

Background*

Dr. Arndt Schottelius serves as the Chief Development Officer of MorphoSys UK Ltd. Dr. Schottelius has been the Chief Development Officer and a Member of Management Board at Morphosys AG since December 29, 2008. He is responsible for coordinating the Group's expanding therapeutic antibody development activities including pre-clinical and clinical drug development. He was employed at Genentech Inc., South San Francisco, where he served as a Director of Immunology, Tissue ...

Read Full Background

Corporate Headquarters*

Lena-Christ-Strasse 48
Martinsried, Bavaria 82152

Germany

Phone: 49 8989 9270
Fax: 49 89 8992 7222

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

There is no Education data available.

Other Affiliations*

Annual Compensation*

Salary€279,531
Bonus€244,590
Total Annual Compensation€524,121

Stock Options*

Restricted Stock Awards€651,773
All Other Compensation€107,437
Exercised Options90,000
Total Number of Options90,000

Total Compensation*

Total Annual Cash Compensation€631,558
Total Short Term Compensation€524,121
Other Long Term Compensation€759,210
Total Calculated Compensation€1,283,331
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOR:GR €77.05 EUR -9.44

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Gustav A. Christensen Chief Executive Officer, President and Director
Dyax Corp.
$615.6K
Daniel M. Junius Chief Executive Officer, President and Director
ImmunoGen, Inc.
$544.5K
Jan G. J. van de Winkel Ph.D.Co-Founder, Chief Executive Officer and President
Genmab A/S
kr10.7M
Edwin Moses Ph.D.Chief Executive Officer and Director
Ablynx NV
--
Randal J. Kirk J.D.Chairman, Chief Executive Officer and President
Intrexon Corporation
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOSYS AG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.